NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.

Individuals Who Provided Content Development and/or Authorship Assistance:
Steven M. Horwitz, MD, Panel Chair, has disclosed that he has received consulting fees from Astex Pharmaceuticals, Celgene Corporation, Janssen Pharmaceutica Products, LP, Kura Oncology, Inc., Kyowa Hakko Kirin Co., Ltd., ADCT, C4 Therapeutics, Curio, Myeloid Therapeutics, Verastem, Seattle Genetics, Inc., and Takeda Pharmaceuticals North America, Inc.; and that he has received grant/research support from Celgene Corporation, Daiichi-Sankyo Co., Forty Seven, Inc., ADCT, Aileron, Corvus, Trillium, Verastem, Portola Pharmaceuticals, Inc., and Seattle Genetics, Inc.
Stephen Ansell, MD, PhD, Panel Vice Chair, has disclosed that he has received grant/research support from Bristol-Myers Squibb, Seattle Genetics, Takeda Pharmaceuticals North America, Inc., AI Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., Trillium Therapeutics Inc., Affimed, and ADC Therapeutics.
Stefan K. Barta, MD, MRCP, MS, Panel Member, has disclosed that he has received grant/research support from Bayer Healthcare, Celgene Corporation, Merck & Co., Inc., and Seattle Genetics, Inc.; consulting fees from Janssen Pharmaceutica Products, LP, and Monsanto; and honoraria from Mundipharma.
Ahmet Dogan, MD, PhD, Panel Member, has disclosed that he has served as a scientific advisor for AbbVie, Inc.; received consulting fees from EUSA Pharma, Seattle Genetics, Inc., and Takeda Pharmaceuticals North America, Inc.; received grant/research support from Genentech, Inc. and Takeda Pharmaceuticals North America, Inc.; and received honoraria from Physicians Education Resource.
Aaron M. Goodman, MD, Panel Member, has disclosed that he has received consulting fees from EUSA Pharma and Seattle Genetics, Inc.
Gaurav Goyal, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Ahmad Halwani, MD, Panel Member, has disclosed that he has received grant/research support from AbbVie, Inc., Bayer HealthCare, Genentech, Inc., Immune Design, Pharmacyclics, and Roche Laboratories, Inc.
Bradley M. Haverkos, MD, MPH, MS, Panel Member, has disclosed that he has received consulting fees from Viracta Therapeutics.
Deepa Jagadeesh, MD, MPH, Panel Member, has disclosed that she has served as a scientific advisor for Kyowa Hakko Kirin Co., Ltd., Atara Biotherapeutics, Veratem, and Seattle Genetics, Inc.; and has received grant/research support from MEI Pharma Inc., Debiopharm, Regeneron Pharmaceuticals, Inc., and Seattle Genetics, Inc.
Neha Mehta-Shah, MD, Panel Member, has disclosed that she receives consulting fees from Kyowa Hakko Kirin Co., Ltd., C4 Therapeutics, and Karyopharm Therapeutics Inc.; and that she has received grant/research support from Bristol-Myers Squibb, Celgene Corporation, Genentech/Roche, Innate Pharma S.A., Verastem, Inc., and Corvus Pharmaceuticals, Inc.
Barbara Pro, MD, Panel Member, has disclosed that she has received grant/research support from Verastem, Inc., Seattle Genetics, Inc., and Takeda Pharmaceuticals North America, Inc.; honoraria from Seattle Genetics, Inc., and Takeda Pharmaceuticals North America, Inc.; and consulting fees from Seattle Genetics, Inc.
Aaron Shaver, MD, PhD, Panel Member, has disclosed that he has no relevant financial relationships.
Lubomir Sokol, MD, PhD, Panel Member, has disclosed that he has received consulting fees from Kyowa Hakko Kirin Co., Ltd.
Basem M. William, MD, Panel Member, has disclosed that he has received consulting fees from Celgene Corporation, Kyowa Hakko Kirin Co., Ltd., Guidepoint Global, and Techspert; and grant/research support from Incyte Corporation and Dova.
Jasmine Zain, MD, Panel Member, has disclosed that she has received consulting fees from Verastem, Mundi Pharma, and Curio Biotech SA; and she is a speaker and has received consulting fees and grant/research support from Seattle Genetics, Inc.
Mary A. Dwyer, MS, CGC, Director, Guidelines Operations, NCCN, has disclosed that she has no relevant financial relationships.
Hema Sundar, PhD, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.

To view all of the conflicts of interest for the panel, go to NCCN.org/disclosures/guidelinepanellisting.aspx.